<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00005792</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-11752</org_study_id>
    <secondary_id>MCC-11752</secondary_id>
    <secondary_id>IRB-4983</secondary_id>
    <secondary_id>NCI-G00-1749</secondary_id>
    <nct_id>NCT00005792</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma</brief_title>
  <official_title>A Study of Intensive-Dose Melphalan, Topotecan, and VP-16 Phosphate (MTV) Followed by Autologous Stem Cell Rescue in Patients With Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lee Moffitt Cancer Center and Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>SmithKline Beecham</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>H. Lee Moffitt Cancer Center and Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation&#xD;
      may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase I/II trial to study the effectiveness of combination chemotherapy plus&#xD;
      peripheral stem cell transplantation in treating patients who have multiple myeloma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the toxicity and potential efficacy of intensive high dose&#xD;
      chemotherapy consisting of melphalan, topotecan, and etoposide phosphate followed by&#xD;
      autologous stem cell transplantation in patients with stage II or III multiple myeloma or&#xD;
      stage I with evidence of progressive disease. II. Determine the maximum tolerated dose of&#xD;
      topotecan in combination with melphalan and etoposide phosphate in this patient population.&#xD;
      III. Determine response rates and time to treatment failure in these patients when treated&#xD;
      with this regimen. IV. Determine the pharmacokinetic profiles of these drugs and investigate&#xD;
      the pharmacodynamic relationships with respect to the efficacy and toxicity of this regimen&#xD;
      in these patients. V. Determine whether the sequencing of this chemotherapy regimen is&#xD;
      appropriate and optimal in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose escalation study of topotecan. Patients are primed with&#xD;
      cyclophosphamide IV over 2 hours for 2 days. Peripheral blood stem cells (PBSC) are&#xD;
      collected. Approximately 4 weeks after PBSC collection, patients receive melphalan IV over 30&#xD;
      minutes and topotecan IV over 30 minutes on days -7 to -5. Etoposide phosphate IV is&#xD;
      administered over 4 hours on days -4 and -3. PBSC are reinfused on day 0. Cohorts of 4-12&#xD;
      patients receive escalating doses of topotecan until the maximum tolerated dose (MTD) is&#xD;
      determined. The MTD is defined as the dose preceding that at which 6 of 12 patients&#xD;
      experience dose limiting toxicities. Patients are followed 2-3 times a week for approximately&#xD;
      1 month, then at 3, 6, and 12 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 34-60 patients will be accrued for this study within 24-36&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2, 1998</start_date>
  <completion_date type="Actual">November 1, 2018</completion_date>
  <primary_completion_date type="Actual">July 1, 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of mucositis</measure>
    <time_frame>5 years</time_frame>
    <description>To determine the incidence and duration of CTCAE v3, grade 3 or 4 mucositis for modified dose level four.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">131</enrollment>
  <condition>Multiple Myeloma</condition>
  <condition>Plasma Cell Neoplasm</condition>
  <arm_group>
    <arm_group_label>MTV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Melphalan Topotecan Etoposide VP-16 Phosphate autologous stem cell transplant</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide phosphate</intervention_name>
    <description>Etoposide phosphate 1363 mg/m^2/day IV over 4 hours (total dose 2726 mg/m^2, or 2400 mg/m^2 etoposide equivalents), beginning 24 hours after the completion of the last infusion of topotecan Days -4, -3</description>
    <arm_group_label>MTV</arm_group_label>
    <other_name>Topotecan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
    <description>Melphalan 50 mg/m^2/day IV over 30 minutes (total dose 150 mg/m^2), followed immediately by topotecan. Days -7, -6, -5</description>
    <arm_group_label>MTV</arm_group_label>
    <other_name>Alkeran(R)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>topotecan</intervention_name>
    <description>Topotecan 3.3 mg/m^2/day (starting total dose = 10 mg/m^2 for level 2) IV over 30 minutes. No topotecan will be administered on the first dose level Days -7, -6, -5</description>
    <arm_group_label>MTV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autologous Stem Cell Rescue</intervention_name>
    <description>reinfusion of stem cells, Day 0</description>
    <arm_group_label>MTV</arm_group_label>
    <other_name>Autologous stem cell transplant</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically confirmed multiple myeloma Newly diagnosed, drug&#xD;
        sensitive (i.e., greater than 50% response to standard chemotherapy), and poor prognostic&#xD;
        indicators (e.g., Salmon-Durie stage III, serum beta-2-microglobulin greater than 3.0 ug/L,&#xD;
        high proliferative fraction, or hypodiploidy) OR Relapsed after a response to standard&#xD;
        chemotherapy OR Primary refractory disease No active leptomeningeal involvement History of&#xD;
        prior CSF tumor involvement without symptoms or signs allowed provided CSF is now free of&#xD;
        disease on lumbar puncture and MRI of brain shows no tumor involvement No severe&#xD;
        symptomatic CNS disease of any etiology&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: 15 to 69 Performance status: ECOG 0-1 ECOG 3-4 secondary to&#xD;
        bone pain or a potentially reversible disease related problem eligible at investigator's&#xD;
        discretion Life expectancy: At least 12 weeks Hematopoietic: Not specified Hepatic:&#xD;
        Bilirubin no greater than 2.0 mg/dL SGOT/SGPT no greater than 2.5 times upper limit of&#xD;
        normal No history of severe hepatic dysfunction Renal: Creatinine no greater than 2.0 mg/dL&#xD;
        OR Creatinine at least 40 mL/min No hemodialysis or peritoneal dialysis Cardiovascular: No&#xD;
        evidence of severe cardiac dysfunction Ejection fraction at least 50% by MUGA scan No major&#xD;
        heart disease Essential hypertension controlled with medications allowed Pulmonary: DLCO at&#xD;
        least 50% of normal No symptomatic obstructive or restrictive pulmonary disease Other: Not&#xD;
        pregnant or nursing Negative pregnancy test Fertile patients must use effective&#xD;
        contraception No psychosocial disorder that would preclude study compliance No active&#xD;
        infections No uncontrolled insulin dependent diabetes mellitus No uncompensated major&#xD;
        thyroid or adrenal dysfunction No other prior malignancy except for nonmelanoma skin cancer&#xD;
        HIV negative&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior total dose&#xD;
        of doxorubicin or daunorubicin greater than 450 mg/m2 No prior topotecan or any other&#xD;
        topoisomerase I inhibitor, etoposide, etoposide phosphate, or teniposide Endocrine therapy:&#xD;
        Not specified Radiotherapy: Not specified Surgery: Not specified Other: No concurrent&#xD;
        nitroglycerin preparations for angina pectoris No concurrent antiarrhythmic drugs for major&#xD;
        ventricular dysrhythmias&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel M. Sullivan, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>H. Lee Moffitt Cancer Center and Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612-9497</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://moffitt.org/clinical-trials-research/</url>
    <description>Moffitt Cancer Center Clinical Trials website</description>
  </link>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>June 2, 2000</study_first_submitted>
  <study_first_submitted_qc>January 30, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2004</study_first_posted>
  <last_update_submitted>November 6, 2019</last_update_submitted>
  <last_update_submitted_qc>November 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>refractory multiple myeloma</keyword>
  <keyword>stage I multiple myeloma</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Topotecan</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

